Logo

ZVSA

ZyVersa Therapeutics, Inc.

ZVSA

ZyVersa Therapeutics, Inc. • NASDAQ
$0.14 ▼ -6.12% (-0.01)
Market Cap $1.12 M
52w High $1.95
52w Low $0.11
Dividend Yield 0%
P/E -0.04
Volume 300
Outstanding Shares 8.10M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $20.752B ▲ $-19.806B ▼ 0% $-2.56 ▼ $-20.752B ▼
Q2-2025 $0 $2.044M ▼ $-2.211M ▲ 0% $-0.46 ▲ $-2.081M ▲
Q1-2025 $0 ▼ $2.145M ▲ $-2.257M ▼ 0% ▲ $-0.73 ▲ $-2.257M ▼
Q4-2024 $26.078K ▲ $1.287M ▼ $-1.422M ▲ -5.452K% ▼ $-1.31 ▲ $-1.287M ▲
Q3-2024 $0 $2.27M $-2.401M 0% $-2.43 $-2.268M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $527.978K ▲ $1.04M ▼ $12.766M ▼ $-11.726M ▼
Q2-2025 $72.086K ▼ $19.641M ▼ $13.541M ▲ $6.1M ▼
Q1-2025 $1.612M ▲ $20.986M ▲ $12.855M ▲ $8.13M ▼
Q4-2024 $1.531M ▲ $20.599M ▲ $12.083M ▼ $8.516M ▲
Q3-2024 $122.921K $19.424M $12.397M $7.027M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-19.806B ▼ $-1.407B ▲ $0 $1.863B ▲ $455.892M ▲ $-1.407B ▲
Q2-2025 $-2.211B ▼ $-1.522B ▲ $0 $-17.718M ▼ $-1.539B ▼ $-1.522B ▲
Q1-2025 $-2.257M ▼ $-1.772B ▼ $0 $1.853B ▲ $80.608M ▲ $-1.772B ▼
Q4-2024 $-1.422M ▲ $-1.225M ▼ $0 $2.633M ▲ $1.408M ▲ $-1.225M ▲
Q3-2024 $-2.401M $-644.401K $0 $647.836K $3.435K $-3.079B

Five-Year Company Overview

Income Statement

Income Statement ZyVersa is a classic early‑stage biotech story: there is essentially no product revenue yet, and the income statement is dominated by research, development, and overhead costs. The company runs at a meaningful loss, which is normal for this stage but still important because it means the business currently consumes cash rather than generates it. Reported per‑share losses look extreme, but that’s largely distorted by large reverse stock splits rather than suddenly worse economics. The core picture is simple: they are spending to advance the pipeline, with no commercial offset yet.

Balance Sheet

Balance Sheet The balance sheet is very thin, with only a small base of assets and equity and very limited cash resources reported. Debt is not a major feature, which reduces financial leverage risk, but the flip side is that the company has little internal cushion to absorb setbacks. Prior negative equity and the need for repeated capital actions suggest the firm has been operating close to the edge and is highly dependent on fresh funding from outside investors to keep progressing its programs.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting ongoing spending on development and corporate costs without incoming revenue. There is essentially no meaningful investment in physical assets, which fits a lean, research‑focused biotech model. The key takeaway is that the company is a cash‑burning enterprise at this stage, and its ability to continue current plans will depend on how reliably it can raise new capital over time.

Competitive Edge

Competitive Edge ZyVersa competes in very crowded spaces—inflammation and kidney disease—but is trying to stand out with differentiated biology. Its inflammasome inhibitor takes a broader, upstream approach than many rivals that target just one inflammasome subtype, and its kidney program addresses a mechanism (lipid buildup in kidney cells) that currently has no direct approved therapies. These features give the company a potentially distinctive position, but that edge is still theoretical until human data clearly shows a benefit against both existing standard treatments and other pipeline competitors. Larger, better‑funded firms in similar areas are a constant competitive pressure.

Innovation and R&D

Innovation and R&D Innovation is the core of ZyVersa’s story. The company is built around two proprietary platforms: one for broad inflammasome inhibition (IC 100) and one for reducing harmful lipid accumulation in the kidneys (VAR 200). Both aim to be first‑in‑class approaches, with early external validation such as foundation grants and progression into mid‑stage trials for the kidney asset. However, everything remains in development: one lead program is in an early clinical trial and the other is still preclinical. The value of this R&D is highly dependent on future trial results, regulatory feedback, and the strength and duration of patent protection.

Summary

Overall, ZyVersa is a high‑risk, high‑uncertainty, early‑stage biotech: no revenue, ongoing losses, a very lean balance sheet, and continued negative cash flow. The scientific story is ambitious and differentiated, with two platforms that could open multiple disease areas if they work as hoped. At the same time, the company’s small financial base, reliance on external funding, and early development stage mean outcomes are highly sensitive to trial data and capital markets. The next few years—driven by mid‑stage kidney trial readouts, first‑in‑human work for the inflammasome program, and success in securing funding or partnerships—will likely define whether this platform can translate from promise to something more durable.

NEWS

November 19, 2025 · 4:20 PM UTC

ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results

Read more

September 10, 2025 · 7:55 AM UTC

ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes

Read more

September 3, 2025 · 7:55 AM UTC

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

Read more